公众号 / 文章心脑血管急症

心房颤动:综述

Atrial Fibrillation: A Review.
PubMed 文献 · JAMA · 2025-01-01
一句话结论2023年ACC/AHA/ACCP/HRS指南推荐:卒中或血栓栓塞年风险≥2%的心房颤动患者应口服抗凝(维生素K拮抗剂或直接口服抗凝药,降低卒中风险60%~80%),多数患者优选直接口服抗凝药而非华法林。

本文综述了美国约1055万成人心房颤动患者的流行病学、临床表现、检测手段及2023年ACC/AHA/ACCP/HRS指南的四阶段分类。指南推荐所有阶段均进行生活方式和危险因素干预;卒中或血栓栓塞年风险≥2%者口服抗凝,直接口服抗凝药(如阿哌沙班、利伐沙班或艾多沙班)因出血风险较低优于华法林,阿司匹林不推荐用于卒中预防。对部分有症状的阵发性心房颤动或射血分数降低的心力衰竭患者,推荐早期节律控制(抗心律失常药物或导管消融)。

要点

  • 卒中或血栓栓塞年风险≥2%的心房颤动患者,口服抗凝(维生素K拮抗剂或直接口服抗凝药)较安慰剂降低卒中风险60%~80%。
  • 多数患者推荐直接口服抗凝药(如阿哌沙班、利伐沙班或艾多沙班)优于华法林,因出血风险较低;阿司匹林疗效较差,不推荐用于卒中预防。
  • 2023年ACC/AHA/ACCP/HRS指南提出心房颤动四阶段:1期有风险(如肥胖、高血压),2期前心房颤动(心电图或影像示心房病变但无心房颤动),3期阵发性(反复发作持续≤7天)或持续性(持续>7天)心房颤动,4期永久性心房颤动。
  • 所有阶段均推荐生活方式和危险因素干预(包括减重和运动)以预防心房颤动发生、复发和并发症。
  • 导管消融是有症状阵发性心房颤动患者的一线治疗,可改善症状并延缓向持续性心房颤动进展;对合并射血分数降低的心力衰竭的心房颤动患者,导管消融也推荐用于改善生活质量、左心室收缩功能和心血管结局(如死亡率和心力衰竭住院率)。

适用人群与场景

  • 美国约1055万成人患有心房颤动;约10%~40%的心房颤动患者无症状。
  • 未诊断心房颤动的缺血性卒中患者,可用植入式循环记录仪(即皮下遥测装置)评估间歇性心房颤动。
  • 心房颤动可在临床就诊、可穿戴设备或心脏植入式电子装置询问时被偶然发现。

诊断标准与关键阈值

  • 2023年ACC/AHA/ACCP/HRS指南写作组提出心房颤动四阶段:1期有风险,定义为存在心房颤动相关危险因素(如肥胖、高血压);2期前心房颤动,心电图或影像显示心房病变但无心房颤动;3期存在阵发性(反复发作持续≤7天)或持续性(连续发作持续>7天)心房颤动亚型;4期永久性心房颤动。
  • 卒中或血栓栓塞年风险估计≥2%是启动口服抗凝的阈值。

处置流程与药物剂量

  • 所有阶段均推荐生活方式和危险因素干预(包括减重和运动),以预防心房颤动发生、复发和并发症。
  • 卒中或血栓栓塞年风险≥2%者,口服抗凝(维生素K拮抗剂或直接口服抗凝药)较安慰剂降低卒中风险60%~80%。
  • 多数患者推荐直接口服抗凝药(如阿哌沙班、利伐沙班或艾多沙班)优于华法林,因出血风险较低。
  • 阿司匹林不推荐用于卒中预防。
  • 2023年ACC/AHA/ACCP/HRS指南推荐对部分心房颤动患者采用抗心律失常药物或导管消融进行早期节律控制,以恢复并维持窦性心律。
  • 导管消融是有症状阵发性心房颤动患者的一线治疗,用于改善症状并延缓向持续性心房颤动进展。
  • 导管消融也推荐用于合并射血分数降低的心力衰竭的心房颤动患者,以改善生活质量、左心室收缩功能和心血管结局(如死亡率和心力衰竭住院率)。

红旗征与不能漏的情况

  • 心房颤动与卒中、心力衰竭、心肌梗死、痴呆、慢性肾脏病和死亡率风险显著增加相关。

研究设计与关键结果

  • 本综述汇总证据:心房颤动症状包括心悸、呼吸困难、胸痛、晕厥前兆、运动不耐受和疲劳,约10%~40%患者无症状;卒中或血栓栓塞年风险≥2%者口服抗凝较安慰剂降低卒中风险60%~80%;多数患者直接口服抗凝药(如阿哌沙班、利伐沙班或艾多沙班)优于华法林;阿司匹林疗效较差且不推荐用于卒中预防;2023年ACC/AHA/ACCP/HRS指南推荐对部分患者早期节律控制,导管消融为有症状阵发性心房颤动一线治疗,并推荐用于合并射血分数降低的心力衰竭的心房颤动患者。

证据类型、等级与局限

  • 证据类型:综述;推荐依据2023年ACC/AHA/ACCP/HRS指南。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对卒中或血栓栓塞年风险≥2%的心房颤动患者,应启动口服抗凝(维生素K拮抗剂或直接口服抗凝药),多数患者优选直接口服抗凝药而非华法林。
  • 不应用阿司匹林替代抗凝用于心房颤动患者的卒中预防。
  • 对所有阶段的心房颤动患者,均应进行生活方式和危险因素干预(包括减重和运动)。
  • 对有症状阵发性心房颤动患者,导管消融可作为一线治疗以改善症状并延缓进展;合并射血分数降低的心力衰竭者,导管消融可改善生活质量、左心室收缩功能和心血管结局。

指南或共识出处

  • 2023年ACC/AHA/ACCP/HRS心房颤动指南

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: In the US, approximately 10.55 million adults have atrial fibrillation (AF). AF is associated with significantly increased risk of stroke, heart failure, myocardial infarction, dementia, chronic kidney disease, and mortality.

OBSERVATIONS: Symptoms of AF include palpitations, dyspnea, chest pain, presyncope, exertional intolerance, and fatigue, although approximately 10% to 40% of people with AF are asymptomatic. AF can be detected incidentally during clinical encounters, with wearable devices, or through interrogation of cardiac implanted electronic devices. In patients presenting with ischemic stroke without diagnosed AF, an implantable loop recorder (ie, subcutaneous telemetry device) can evaluate patients for intermittent AF. The 2023 American College of Cardiology (ACC)/American Heart Association (AHA)/American College of Clinical Pharmacy (ACCP)/Heart Rhythm Society (HRS) Guideline writing group proposed 4 stages of AF evolution: stage 1, at risk, defined as patients with AF-associated risk factors (eg, obesity, hypertension); stage 2, pre-AF, signs of atrial pathology on electrocardiogram or imaging without AF; stage 3, the presence of paroxysmal (recurrent AF episodes lasting ≤7 days) or persistent (continuous AF episode lasting >7 days) AF subtypes; and stage 4, permanent AF. Lifestyle and risk factor modification, including weight loss and exercise, to prevent AF onset, recurrence, and complications are recommended for all stages. In patients with estimated risk of stroke and thromboembolic events of 2% or greater per year, anticoagulation with a vitamin K antagonist or direct oral anticoagulant reduces stroke risk by 60% to 80% compared with placebo. In most patients, a direct oral anticoagulant, such as apixaban, rivaroxaban, or edoxaban, is recommended over warfarin because of lower bleeding risks. Compared with anticoagulation, aspirin is associated with poorer efficacy and is not recommended for stroke prevention. Early rhythm control with antiarrhythmic drugs or catheter ablation to restore and maintain sinus rhythm is recommended by the 2023 ACC/AHA/ACCP/HRS Guideline for some patients with AF. Catheter ablation is first-line therapy in patients with symptomatic paroxysmal AF to improve symptoms and slow progression to persistent AF. Catheter ablation is also recommended for patients with AF who have heart failure with reduced ejection fraction (HFrEF) to improve quality of life, left ventricular systolic function, and cardiovascular outcomes, such as rates of mortality and heart failure hospitalization.

CONCLUSIONS AND RELEVANCE: AF is associated with increased rates of stroke, heart failure, and mortality. Lifestyle and risk factor modification are recommended to prevent AF onset, recurrence, and complications, and oral anticoagulants are recommended for those with an estimated risk of stroke or thromboembolic events of 2% or greater per year. Early rhythm control using antiarrhythmic drugs or catheter ablation is recommended in select patients with AF experiencing symptomatic paroxysmal AF or HFrEF.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Ko D, Chung MK, Evans PT, et al. Atrial Fibrillation: A Review. JAMA. 2025. PMID: 39680399. doi:10.1001/jama.2024.22451

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。